Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...
After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...
Currently, Rilparencel’s Phase 3 is planned to deliver full data by Q3 2027 if no surrogate endpoint is found that’s suitable ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
The U.S. will ban nearly all uses of the common industrial cleaning agent, trichloroethylene (TCE), this year—more than 50 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback